Grivcheva stardelova, Kalina
Preferred name
Grivcheva stardelova, Kalina
Official Name
Grivcheva stardelova, Kalina
Main Affiliation
Email
kalina.grivcheva.stardelova@medf.ukim.edu.mk
38 results
Now showing 1 - 10 of 38
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, COVID-19 in the endoscopy unit: How likely is transmission of infection? Results from an international, multicenter study(Baishideng Publishing Group Inc., 2021-09) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, ESPEN practical guideline: Clinical Nutrition in inflammatory bowel disease(Elsevier Ltd., 2020-01) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Diagnostic Potential of Calprotectin for Spontaneous Bacterial Peritonitis in Patients Withliver Cirrhosis and Ascites(Walter de Gruyter GmbH / Macedonian Academy of Sciences and Arts, 2021-12-30); ; ; ; The development of spontaneous bacterial peritonitis (SBP) is a serious and life-threatening condition in patients with cirrhosis and ascites. The aim of this study was to determine the diagnostic potential of calprotectin in ascites, for SBP in patients with liver cirrhosis and ascites before and after antibiotic treatment and to compare the mean values of calprotectin in ascites in patients with and without SBP. This prospective-observational study was comprised of 70 patients with cirrhosis and ascites, divided into two groups, the SBP and the non-SBP group. Quantitative measurements of calprotectin in ascites was completed with the Quantum Blue Calprotectin Ascites test (LF-ASC25), using the Quantum Blue Reader. The average value of calprotectin in the SBP group was 1.5 ± 0.40 μg / mL, and in the non-SBP group it was lower (0.4 ± 0.30). The difference between the mean values was statistically significant with p <0.05. The mean value of calprotectin in ascites before therapy among the SBP group was 1.5 ± 0.4, and after antibiotic therapy, the value decreased significantly to 1.0 ± 0.6; the difference between the mean values was statistically significant with p <0.05. ROC analysis indicated that calprotectin contributed to the diagnosis of SBP with a 94.3% sensitivity rating (to correctly identify positives), and the specificity was 62.5%, which corresponded to the value of 0.275. Our research confirmed that ascitic calprotectin was a good predictor, and is significantly associated with the occurrence of SBP in patients with liver cirrhosis. By monitoring the value of calprotectin in ascites on the 7th day of antibiotic treatment, the effectiveness of antibiotic treatment in patients with SBP can be determined. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Case report-patient with cerebellar stroke and percutaneous enterogastric tube(2017); ; ; Babunovska MarijaAbstract Introduction: Cerebellar strokes occur in 1,5-2,3% of all ischemic stroke cases. Aim: We present 74-year-old male patient, admitted at the University Clinic of neurology due to acute ischemic cerebellar stroke with speech and swallowing difficulties, disturbed balance, weakness of the left side extremities, impaired consciousness. Case report: On admission the patient was presented with clinical picture of left hemicerbellar syndrome with compression of the medulla. Computer tomography of the brain (CT)on admission was with normal finding. Control CT of the brain after 48 hours showed irregular ischemic lesion in the left cerebellar hemisphere. Nuclear magnetic resonance imaging (MRI) of the brain confirmed the CT findings. Color duplex sonography of the vertebral arteries (VA)showed reduced Doppler signal in the left VA,finding conclusive with distal occlusion and compensatory increased blood flow velocity in the right VA. CT angiography of vertebral arteries showed hypoplastic extracranial segment of the left VA, while its intracranial segment could not be visualized. Posterior inferior cerebellar artery (PICA) was not visualized intracranially as well, finding conclusive with its occlusion. The right VA on CT angiography was seen with compensatory increased lumen. Patient was treated with usual therapy for ischemic stroke during a period of 3 weeks. Due to dysphagia, nasogastric feeding tube was placed. During the stay in hospital, the patient's physical and neurologicl status gadually improved, But, dysphagia still persisted and according to current guidelines for stroke treatment, together with the specialists from the Clinic of Gastroenterohepatology, we decided to place a percutaneous enterogastric tube (PEG). The intervention went very well and the patient was discharged for home treatment. He came for regular control check-ups every month for a period of 1 year. His physical and neurological symptoms gradually improved, and his swallowing function recovered. After 6 months, the PEG probe was taken out, and the patient continued to eat and swallow normally. Discussion: Dysphagia is a serious complication after stroke. It carries risk for aspiration and occurrence of pneumonia. Placement of nasogastric feeding tube is recommended in patients who have swallowing difficulties in the acute phase of stroke. Placement of PEG tube is recommended 2 weeks after stroke occurrence. Studies so far have shown that feeding through the PEG tube is more efficient than feeding through the nasogastric tube in terms of improved nutritive status and has lower complication risk. Conclusion: Successful treatment of stroke depends on many factors. Particular attention should be brought to the food and beverage intake, and assessment of early signs and risk factors of dysphagia in order to take appropriate therapeutic measures. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Evaluation of the Effects of Gastro Protect as an Alternative Medicine on Gastritis and Other Gastrointestinal Symptoms(Macedonian Academy of Sciences and Arts, 2024-03-01); ; ; ; Introduction: The use of herbal medicine as a part of the Complementary and Alternative Medicine is increasing worldwide. Herbal remedies are used to better different conditions including gastritis. Material and Methods: We conducted a prospective randomized control clinical trial on a total sample of 72 patients with gastritis in order to examine the effects of the commercial herbal product Gastro Protect. After 6 weeks of conventional therapy the patients were divided into two groups with 36 patients each. As a continuation of the treatment, Group 1 received conventional therapy + Gastro Protect and Group 2 received conventional therapy + Placebo. We analyzed 14 selected gastrointestinal symptoms, five related to digestive problems, and nine related to stool and bowel problems. For assessing the selected symptoms we used seven point gastrointestinal symptom rating scale (GSRS). Results: The Gastro Protect group had a significantly lower GSRS score (better condition) compared to the Placebo group related to all five selected symptoms of digestive problems as: abdominal pain (p=0.0250), hunger pain (p=0.0276), nausea (p=0.0019), heartburn (p=0.00001), and acid reflux (p=0.0017). The Gastro Protect group, also had a significantly lower GSRS score (better condition) compared to the Placebo group related to three out of nine selected bowel symptoms: rumbling (p=0.0022), abdominal distension (p=0.0029), and gas or flatus (p=0.0039). Conclusion: Gastro protect was effective in treating gastritis and other gastrointestinal symptoms. It was safe for usage and showed almost no side effects. In our study, Gastro Protect reduced the examined gastric symptoms and related examined intestinal symptoms. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Biologic Therapy in Inflammatory Bowel Disease - Results from a Single Tertiary Care Center in North Macedonia(Македонска академија на науките и уметностите, Одделение за медицински науки = Macedonian Academy of Sciences and Arts, Section of Medical Sciences/Walter de Gruyter GmbH, 2023-07-01); ; ; ; Medical therapies used for Inflammatory Bowel Disease (IBD) include conventional (e.g. 5-aminosalicylates, steroids, immunomodulators) and biologic (e.g. inhibitors of tumor necrosis factor - alpha, integrin inhibitors, interleukin inhibitors) medications. Biologics, due to their high cost, were unfortunately not covered by the public health insurance system in North Macedonia until 2019 and, therefore, not widely utilized for our IBD patients. In 2019, the University Clinic of Gastroenterology and Hepatology in Skopje developed a biologic therapy supply, provided by the National Health Insurance Fund, making this therapy available for a larger number of patients. This report presents the initial results of our prospective, single tertiary-care center study on the effects of biologic therapy in patients with IBD in North Macedonia. The study is focused on the evaluation of clinical outcomes after anti-tumor necrosis factor alpha (anti TNF-alpha) therapy in IBD patients with prior inadequate response to conventional medications. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Comorbid Conditions in a Cohort of Inpatients with SARS-CoV-2 and their Association with In-Hospital Mortality During the Early Phases of the Pandemic(Macedonian Academy of Sciences and Arts/Walter de Gruyter GmbH, 2023-12-01); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, PP222-MON MALNUTRITION IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE – FREQUENCY AND NUTRITIONAL ASSESSMENT(Elsevier BV, 2011); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, PREDICTIVE POTENTIAL OF BLOOD AND ASCITIC FLUID LABORATORY PARAMETERS FOR SPONTANEOUS BACTERIAL PERITONITIS IN PATIENTS WITH CIRRHOSIS(Georgian Association of Business Press, 2021-12); ; ; ; Patients with spontaneous bacterial peritonitis (SBP) usually have serious complications associated with deteriorating synthetic and excretory function of the liver cells, and require hospitalization and regular monitoring of biochemical parameters in blood and ascites.Aims - to determine the average values of laboratory parameters in blood and ascites in patients with SBP, to determine whether there is a difference in the average values between patients with SBP and non-SBP as well as their predictive power for the diagnosis of SBP.The study was designed as a prospective-analytical-observational and was conducted at the University Clinic for Gastroenterohepatology in Skopje for a period of one year. The study population included hospitalized patients with established liver cirrhosis, regardless of etiology; 70 patients, divided into two groups, 35 patients with SBP and 35 non-SBP. The selection of patients who were included in the study was conducted according to pre-determined inclusion and exclusion criteria. All diagnostic test specimens were immediately referred to the Central Clinical Laboratory. Five ml of a total of 10 ml of ascites were used for automatic counting of PMNC, and 5 ml for biochemical analysis of ascites (total sweat-WP). At the same time, for the needs of biochemical blood tests, a venipuncture of 10 ml of blood was performed.The univariate analysis showed that INR, albumin/s, creatinine/s, TP/ascites (p=0.039, p=0.035, p=0.013, p=0.000, p=0.030) were independent risk factors for the development of SBP. INR>1.2 significantly increased the chance of SBP by three times (Exp (B) = 3.222 (CI (1.063-9.768)). Serum albumin<35 g/L significantly increased the chance of SBP by five and a half times (Exp (B) = 5.712 (CI (1.135-28.748). Creatinine/s>115 µmol/L significantly increased the chance of SBP by four times (Exp (B) = 4.070 (CI (1.352-12.255)).TP in ascites ≤10 significantly increased the chance of SBP by five times (Exp (B) = 5.337 (CI (6.243-416.469). The multivariate logistic analysis confirmed that INR>1.2 and creatinine>115 µmol/L were statistical risk factors (predictors) that increased the chance of SBP.Low serum albumin values are independent risk factors for predicting SBP and significantly increase the risk of developing SBP by five and a half times. Patients with SBP have lower mean TP values in ascites than non-SBP. Low TP values in ascites<11g/L are independent risk factors for the development of SBP and significantly increase the risk of SBP by five times. Of course, additional and larger studies are necessary in order to confirm our conclusion in the future. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, ESPEN guideline on Clinical Nutrition in inflammatory bowel disease(Elsevier BV, 2023-03)